Focused On-demand Library for Peroxisomal membrane protein 11B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O96011

UPID:

PX11B_HUMAN

Alternative names:

Peroxin-11B; Peroxisomal biogenesis factor 11B; Protein PEX11 homolog beta

Alternative UPACC:

O96011; B3KN85; B4DXH9; Q96ET2

Background:

Peroxisomal membrane protein 11B, also known as Peroxin-11B, plays a crucial role in peroxisomal proliferation. It is instrumental in regulating peroxisome division by facilitating the recruitment of the dynamin-related GTPase DNM1L to the peroxisomal membrane, promoting membrane protrusion and elongation.

Therapeutic significance:

Peroxisomal membrane protein 11B is linked to Peroxisome biogenesis disorder 14B, characterized by mild intellectual disability, congenital cataracts, and progressive hearing loss. Understanding its role could lead to novel therapeutic strategies for this disorder.